Analyst Price Targets — EVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 9:58 am | Swayampakula Ramakanth | H.C. Wainwright | $4.00 | $2.14 | TheFly | Evotec price target lowered to $4 from $7 at H.C. Wainwright |
| July 15, 2026 6:51 am | — | Macquarie | $2.00 | $2.14 | StreetInsider | TD Cowen Downgrades Evotec (EVO) to Hold |
| August 14, 2025 10:04 am | Douglas Tsao | H.C. Wainwright | $7.00 | $3.81 | TheFly | Evotec price target lowered to $7 from $8 at H.C. Wainwright |
| August 15, 2024 6:39 am | Douglas Tsao | H.C. Wainwright | $8.00 | $3.22 | StreetInsider | Evotec (EVO) PT Lowered to $8 at H.C. Wainwright |
| April 25, 2024 6:39 am | Douglas Tsao | H.C. Wainwright | $11.00 | $5.23 | StreetInsider | Evotec (EVO) PT Lowered to $11 at H.C. Wainwright |
| December 9, 2022 6:39 am | — | H.C. Wainwright | $12.00 | $8.38 | Benzinga | HC Wainwright & Co. Initiates Coverage On Evotec with Buy Rating, Announces Price Target of $12 |
Latest News for EVO
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors PR New
Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY® BiTco designed to boost T cell activation by engaging a costimulatory signaling pathway LOGIBODY® designed to enhance precision of T cell activation based on multispecific antigen signature HAMBURG, Germany and HALLBERGMOOS,…
Evotec AG (NASDAQ: EVO - Get Free Report) has been given a consensus recommendation of "Hold" by the five analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company.
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases PR Newswire
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need HAMBURG, Germany, Aug. 6, 2026…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EVO.
U.S. House Trading
No House trades found for EVO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.